講演・口頭発表等 - 横田　隆徳

61. Sano T,Nagata T,Tanaka K,Ebihara S,Mochizuki H,Hasegawa M,Yokota T. Inhibition of SNCA Propagation by locally injected ASO in wt mice. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31

62. Akaza M,Kawabata S,Watanabe T,Miyano Y,Mizuguchi R,Kaminaka S,Iida S,Sasaki T,Adachi Y,Sekihara K,Sumi Y,Okawa A,Yokota . The evaluation of nerve activity using magnetic field measurement and positional information by US. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

63. Nishi R,Ohyagi M,Nagata T,Mabuchi Y,Yokota T. DNA/RNA heteroduplex oligonucleotide technology for regulating activated microglia and macrophages. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31

64. Yokote H,Toru S,Nishida Y,Hattori T,Sanjo N,Yokota T. Association between serum amyloid A and cortical volume in patients with multiple sclerosis. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

65. Aoki H,Higashi M,Okita M,Yokota T,Ishikawa K. Expression of thymidine kinase 2 and mitochondrial proteins in SCA31 human brains. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

66. Ohara M,Takagi K,Yoshida K,Maeda Y,Hara R,Sato K,Nagata T,Wada T,Yokota T. Development of antidote for therapeutic oligonucleotides which reduces the acute toxicity. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31

67. Jia C,Yoshioka K,Lei Mon S,Tanaka K,Nagata T,Yokota T. Heteroduplex Oligonucleotides technology improves therapeutic index for CNS diseases. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31

68. Maruoka H,Hattori T,Orimo S,Yokota T. Graph theoretical analysis of structural brain network of Alzheimer's disease patients. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

69. Yoshioka K,Kunieda T,Asami Y,Tanaka K,Piao W,Kuwahara H,Nishina K,Nagata T,Yokota T. Treatment for FAP with overhanging heteroduplex oligonucleotides by transferrin-mediated delivery. 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

70. Yokota T,Nagata T,Dwyer C,Yoshida K,Yoshioka K,Seth P,Rigo F,Bennett F. Development of BBB-penetrating heteroduplex oligonucleotides(HDO). 61st Annual Meeting of the Japanese Society of Neurology 2020.08.31 Okayama

71. Takanori Yokota. New Stage of DNA/RNA Heteroduplex Oligonucleotide. Asia TIDES:Oligonucleotide & Peptide Therapeutics 2020.02.24 kyoto

72. Kotaro Yoshioka. Heteroduplex-Oligonucleotides　for　Highly　Efficient　Silencing　of　microRNA　through　a　Novel　intracellular Mechanism. 2019　Oligonucleotides　Meeting 2019.11.16 Munich

73. Takanori Yokota. Systemically Administered DNA/RNA Heteroduplex Oligonucleotides That Can Efficiently Regulate CNS Genes*. TIDES Europe2019:Oligonucleotide &Peptide Therapeutics 2019.11.13 Amsterdam

74. Amano A,Sanjo N,Nakakido M,Tsumoto K,Matsubara E,Furukawa F,Nishida Y,Saito T,Saido T,Yokota T,. Quantitative evaluation of Aβ oligomer in mouse brain using dot blot method. 第38回日本認知症学会学術集会 2019.11.07 新宿

75. Otani Tai, Iwase Ryo, Takahashi Yuko K., Soga Kazumasa, Kim Yangsu, Igarashi Susumu, Kaneko Kimihiko, Takahashi Toshiyuki, Irioka Takashi, Yokota Takanori. MOG抗体陽性中枢神経疾患の多様性(A Variety of Myelin Oligodendrocyte Glycoprotein Antibody Positive Central Nervous System Disorders). 臨床神経学 2019.11.01

76. Yokota Takanori. トランスレーショナルリサーチ後の時代における運動ニューロン疾患　ALS治療のオリゴヌクレオチド薬(Motor neuron diseases in the era after translational research　Oligonucleotide drug for treatment of ALS). 臨床神経学 2019.11.01

77. Ishiguro Taro, Yokota Takanori, Ishikawa Kinya, Nagai Yoshitaka, Petrucelli Leonard. ショウジョウバエのSpt4ノックダウンはSCA31関連の伸長UGGAAリピート誘発毒性を抑制する(Spt4 knockdown suppressed SCA31-linked expanded UGGAA repeat-induced toxicity in Drosophila). 臨床神経学 2019.11.01

78. Irioka Takashi, Motomura Masakatsu, Uchihara Toshiki, Shintaku Hiroshi, Ishikawa Kinya, Igarashi Susumu, Majima Takamasa, Takahashi Yuko K., Iwase Ryo, Otani Tai, Kitanosono Hiroko, Shiraishi Hirokazu, Tsuura Yukio, Yokota Takanori. カルシウムチャネル抗体関連小脳失調症患者の臨床病理学的研究(Clinicopathological study of a patient with calcium channels antibody-associated cerebellar ataxia). 臨床神経学 2019.11.01

79. Sanjo Nobuo, Shishido-Hara Yukiko, Nose Yurie, Yokota Takanori. 疾患修飾療法時代の進行性多巣性白質脳症　炎症の制御と免疫システムの制御はPMLの良好な予後と関連している(Progressive multifocal leukoencephalopathy in the era of disease-modifying therapies　A controlled inflammation and a regulatory immune system are associated with better prognosis of PML). 臨床神経学 2019.11.01

80. Iwase Ryo, Irioka Takashi, Takahashi Yuko K., Igarashi Susumu, Otani Tai, Soga Kazumasa, Yokota Takanori. 血管内リンパ腫(IVL)3症例の臨床および神経放射線学的研究(Clinical and neuroradiological study of 3 patients with intravascular lymphoma(IVL)). 臨床神経学 2019.11.01